The recent COVID-19 carries potential risk factors for VTE and worse clinical course in some patients has an association with thrombosis. While low molecular weight heparins are under investigation for appropriate dosage, other elements could be useful. We share our experience about two patients with unexpected clinical course.

Early antithrombotic therapy and COVID-19: a better clinical course? New evidences from real-life cases

Egidio Imbalzano
Secondo
Investigation
;
Claudia Morabito
Investigation
;
Marianna Gigliotti De Fazio
Investigation
;
Giuseppe Dattilo.
Ultimo
Validation
2020-01-01

Abstract

The recent COVID-19 carries potential risk factors for VTE and worse clinical course in some patients has an association with thrombosis. While low molecular weight heparins are under investigation for appropriate dosage, other elements could be useful. We share our experience about two patients with unexpected clinical course.
2020
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11570/3181426
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 2
social impact